跳至主要内容
临床试验/NCT02805881
NCT02805881已完成不适用

Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)

Neurolief Ltd.1 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2016年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
28
试验地点
1
主要终点
Hamilton Depression Rating Scale (HDRS21)

研究概览

简要总结

Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The subject is capable of understanding the study and to sign an informed consent.
  • Subject is between the ages of 18 to 65 years old.
  • Unipolar major depressive disorder
  • Score on the Hamilton Depression Rating Scale (HDRS21) > 22
  • Current MDD episode >3 months
  • Nonresponse with >6 week use of one to six antidepressant in current episode

排除标准

  • History of neurosurgical interventions.
  • Subjects with metal implants or shrapnel in their head, except for dental implants.
  • Skin lesion or inflammation at the region of the stimulating electrodes.
  • Pregnancy or Lactation.
  • Women of reproductive age not using efficient contraceptive method.
  • History of cerebrovascular event.
  • Psychotic or bipolar depression
  • History of schizophrenia, schizoaffective disorder or other non-mood disorder psychosis
  • Current delirium, dementia, amnestic disorder or other cognitive disorders
  • Clinically significant current suicidal intent as assessed by the investigator team.
  • Obsessive-compulsive disorder or post-traumatic stress disorder
  • Alcohol and non-alcohol psychoactive substance abuse or dependence
  • Significant cardiac, medical, or progressive neurological or medical illness
  • An implantable electrical device such as a pacemaker.

结局指标

主要结局

Hamilton Depression Rating Scale (HDRS21)

时间窗: 6 weeks

Change in the total score on the Hamilton Depression Rating Scale (HDRS21) from baseline (visit 1) to week 6 (visit 4).

Incidence of Treatment-Emergent Adverse Events

时间窗: 6 weeks

Safety measures will be recorded and evaluated at every evaluation visit. It will be coded using the Medical Dictionary for Regulatory Activities. Vital signs (blood pressure and pulse) will be assessed and documented at each evaluation visit.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验